Measuring Activity in the Ubiquitin–Proteasome System: From Large Scale Discoveries to Single Cells Analysis by Melvin, Adam T. et al.
Measuring activity in the ubiquitin-proteasome system: From
large scale discoveries to single cells analysis
Adam T. Melvin1, Gregery S. Woss1, Jessica H. Park1, Marcey L. Waters1, and Nancy L.
Allbritton1,2
1Department of Chemistry, University of North Carolina, Chapel Hill, NC 27599
2Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC 27599 and
North Carolina State University, Raleigh, NC 27695
Abstract
The ubiquitin proteasome system (UPS) is the primary pathway responsible for the recognition
and degradation of misfolded, damaged, or tightly regulated proteins in addition to performing
essential roles in DNA repair, cell cycle regulation, cell migration, and the immune response.
While traditional biochemical techniques have proven useful in the identification of key proteins
involved in this pathway, the implementation of novel reporters responsible for measuring
enzymatic activity of the UPS have provided valuable insight into the effectiveness of therapeutics
and role of the UPS in various human diseases such as multiple myeloma and Huntington’s
disease. These reporters, usually consisting of a recognition sequences fused to an analytical
handle, are designed to specifically evaluate enzymatic activity of certain members of the UPS
including the proteasome, E3 ubiquitin ligases, and deubiquitinating enzymes (DUBs). This
review highlights the more commonly used reporters employed in a variety of scenarios ranging
from high-throughput screening of novel inhibitors to single cell microscopy techniques
measuring E3 ligase or proteasome activity. Finally, recent work is presented highlighting the
development of novel degron-based substrate designed to overcome the limitations of current
reporting techniques in measuring E3 ligase and proteasome activity in patient samples.
Introduction
Degradation of regulatory, damaged, and misfolded proteins is essential to proper cellular
homeostasis (1). In eukaryotes the targeting and controlled degradation of these proteins is
governed by the ubiquitin proteasome system (UPS). Posttranslational protein modification
by ubiquitin (Ub) targets the protein to the 26S proteasome, which unfolds and degrades the
protein into small peptide fragments. Protein ubiquitination requires a cascade of three
increasingly diverse enzymes (Figure 1). First, an E1 ubiquitin activating enzyme forms an
ATP-dependent high-energy thioester bond with free ubiquitin. Next, the Ub∼E1 complex
interacts with an E2 ubiquitin conjugating enzyme, transferring the ubiquitin from E1 to E2.
The Ub∼E2 complex proceeds to interact with a third class of enzymes, the E3 ubiquitin
ligases, which mediates either the direct (RING family E3 ligases) or indirect (HECT family
E3 ligases) transfer of ubiquitin to a proximal lysine on the targeted protein (2). The
recognition of the target protein occurs through a unique degradation signal, or degron.
There are many different classes of degrons including phospho-degrons, oxygen-dependent
degrons, and N-degrons (3). Following initial ubiquitin-protein conjugation, additional
ubiquitins are added to form a polyubiquitin (polyUb) chain. This polyubiquitin chain can be
linked via one of seven different lysine residues found on ubiquitin (e.g. K48, K63, or K11)
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or through the N-terminal methionine residue to form a linear ubiquitin chain (4). The
manner in which the polyubiquitin chain is formed dictates the outcome of the protein, with
K48-linked chains being targeted toward the proteasome for degradation while K63-linked
chains play a role in cell signaling, DNA damage repair, and endocytic trafficking (5).
Further, the number of conjugated ubiquitins (mono- vs. multiple mono- vs. poly-
ubiquitination) can also decide the eventual fate of the modified protein.
A poly-ubiquitinated protein targeted for degradation is recognized by the 19S cap of the
26S proteasome, where the target protein is deubiquitinated, unfolded, and degraded by the
20S core particle (6). The barrel shaped 20S core consists of four heptameric rings, with the
inner rings consisting of β-subunits, three of which are responsible for the catalytic cleavage
of a protein. Control of polyubiquitin chain formation is further refined by another class of
proteins, deubiquitinating enzymes (DUBs). DUBs are capable of cleaving the isopeptide
bond between ubiquitin and the target protein, initiating either the rescue of a poly-
ubiquitinated protein or the recycling of ubiquitin from the proteasome (Figure 1). The E1-
E3 enzymatic cascade is paralleled by several ubiquitin-like proteins (UbL) (Figure 1).
Examples include SUMO (small ubiquitin like modifier), ISG15 (interferon stimulated gene
15), and NEDD8 (neural precursor cell expressed developmentally down regulated protein
8) all of which are activated and conjugated to proteins using similar machinery. It has
become increasingly apparent that these UbLs play an integral role in the regulation of
cellular processes, including transcriptional regulation and DNA repair (7). In a process
reminiscent of DUBs in the ubiquitin pathway, the isopeptide bond between an UbL and a
protein is cleaved by UbL proteases allowing them to function as a reversible post-
translational modification.
The unique and vital functions carried out by the UPS in regulating protein levels have made
it a very attractive target for novel therapeutics. This interest has been compounded by the
clinical success of the proteasome inhibitor Bortezomib in the treatment of multiple
myeloma (8). Dysregulation of protein production, particularly antibodies, in this cancer can
create an increased reliance on the proteasome to degrade misfolded or overproduced
proteins. Incomplete inhibition of the proteasome proves too stressful for cancer cells, while
proving less cytotoxic to healthy cells. This permits a more targeted treatment approach
relative traditional cancer therapies and has led to the development of the next generation
proteasome inhibitor Carfilzomib (9). Members of the UPS are also thought to play a direct
role in other cancers and neurodegenerative disease. Though there are conflicting reports,
decreased proteasome activity is suspected to play a key role in conformational diseases
such as Parkinson’s and Huntington’s disease (10). These diseases are characterized by the
accumulation of misfolded proteins and decreased proteasome activity, potentially
implicating the proteasome as a pivotal target. Mutations of UPS components may also play
a role in neurodegenerative disorders, such as the frame shifted ubiquitin UBB+1 which
consists of an extra 19 amino acids on the Ub C-terminus resulting in an inability to be
activated by E1 enzymes. Further, the tumor suppressor p53 and its E3 ligase Mdm2 (or
Hdm2 in humans) demonstrate an additional role for the UPS in disease. Strict regulation of
p53 is maintained by constant degradation in healthy cells; however, when under genotoxic
stress p53 degradation is suppressed. Accumulation of p53, in turn, leads to an upregulation
of genes associated with apoptosis or growth. Due to the prominent role of p53 in many
cancers, the role of the UPS in its regulation has become an area of intense interest (11,12).
Finally, it has been demonstrated that deregulation of DUBs is also associated with human
disease (13). DUBs such as CYLD and USP9 have been found to be mutated in cancers,
suggesting their potential status as oncogenes.
Due to the increased interest in targeting the UPS for clinical therapeutics, it has become
necessary to create new metrics to evaluate the enzymatic activity of the members of the
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UPS including the proteasome, E3 ligase, and DUBs. In this review we survey common
reporters and reporting techniques that have been used to detect not only enzymatic activity,
but also the relative success of novel inhibitors targeting the UPS. We highlight reporters
that evaluate the proteasome as well as members of the ubiquitin enzymatic cascade
including E3 ligases, DUBs and polyubiquitin chain formation. Finally, we present some
recent work from our lab detailing the development and characterization of a novel
substrate, based on the degron from β-Catenin, as the groundwork for the next generation of
E3 ligase and proteasome reporters.
Measuring proteasome activity
Several strategies have been developed to create reporters capable of directly measuring
proteasome activity. The majority of these reporters consist of two major elements: a
targeting sequence to recruit the reporter to the proteasome and an analytical handle that can
produce a measureable signal. There are number of different schemes to target the
proteasome, which is reflected in the number of successful reporters described in the
literature. By far the most popular analytical handles are photometric so that microscopy-
based imaging and spectrometric technologies, as well as FACS, can be used for sensor
read-out. In this section we discuss these reporting methods and highlight recent work
targeting a reporter to the proteasome.
Ubiquitin-dependent proteasome targeting
The earliest strategies for targeting a reporter to the proteasome exploited known
degradation signals. Strong degrons, such as CL1, allow reporters to be ubiquitinated in an
E3 ligase-mediated fashion. Indeed, one popular reporter which makes use of this approach
is GFPu (Figure 2a). This reporter consists of the sixteen amino acid CL1 degron fused to
green fluorescent protein (GFP) (14). Cells stably transfected with the reporter express GFPu
constitutively which is immediately recruited to the proteasome for degradation after
synthesis. Cellular concentrations of the reporter are low, yielding low levels of cellular
fluorescence; however, inhibition of the proteasome by compounds such as MG-132 or
Bortezomib causes an accumulation of GFPu resulting in increased cellular fluorescence
This reporting technique has also been used to demonstrate the importance of α-Synuclein-
mediated inhibition of the proteasome (15). Of particular interest are transgenic mouse
models expressing GFPu, which have been used to investigate proteasome activity in
neurons. One study using this model demonstrated that proteasome activity is not impaired
in neurons as a function of aging (16). These models have elucidated the contribution of the
proteasome to protein-conformation diseases such as Huntington’s disease and revealed that
GFPu does not accumulate in mouse models of Huntington’s disease, calling into question a
link between cellular proteasome activity and protein aggregation (17).
Another equally important targeting mechanism fuses a non-cleavable ubiquitin (G76V) to
an analytical handle such as GFP (this reporter is called UbV-GFP). The single ubiquitin
promotes polyubiquitin chain formation to ultimately target the reporter to the proteasome
while minimizing the threat of isopeptide bond cleavage by DUBs (Figure 2b) (18). Notably,
the UbV-GFP reporter has been successfully implemented in Caenorhabditis elegans,
allowing for in vivo mapping of proteasomal activity in response to elevated levels of
unfolded protein or heat stress. In certain mutants, which exhibited a hypersensitivity to
stress, mildly increased levels of unfolded protein resulted in an accumulation of the
reporter, while heat stress resulted in enhanced proteasomal activity (19). An interesting
reporter related to UbV-GFP incorporates a photoconvertible fluorescent protein, Dendra2,
which could be converted from a green to red fluorescent state immediately prior to
measurement. This reporter was used in C. elegans to monitor proteasome activity
independent of new protein production, as newly synthesized protein would remain in a
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green fluorescent state (20). Ubiquitin dependent reporters have proven to be both popular
and effective in monitoring overall proteasome activity; however, it is important to keep in
mind when dealing with reporters that utilize the ubiquitination machinery that the E1-E3
enzymatic cascade is strongly linked to the proteasome. As such, these reporters must be
carefully designed to minimize convolution of proteasome activity with other UPS activity.
Ubiquitin-independent proteasome targeting
An effective way of minimizing the potential effects of E3 ligases is to design a reporter
independent of this enzymatic cascade. One such reporting strategy is the fusion of a tetra-
ubiquitin chain to the enzyme luciferase. Similar to GFPu, following proteasome inhibition
transfected tetra-ubiquitin-luciferase accumulates in cells catalyzing a bioluminescent
reaction for quantification of proteasome activity. Reporters employing this strategy have
been used to study the proteasome in high-throughput cellular assays and across several
species at the organismal level. These studies have revealed a 5-fold difference between the
proteasome processivity of yeast and mammals (21). This reporter has been also used
successfully in one study to screen for proteasome inhibitors (22). The work examined
∼18,000 molecules and ∼15,000 plant extracts, discovering 21 molecules and 66 extracts
capable of inhibiting the proteasome (23). Additionally, this reporter has been used to great
effect in the imaging of the proteasome at the organismal level. Xenografted tumors in mice
were shown to rapidly degrade the reporter under normal circumstances; however the effect
was abrogated in a time and concentration dependent fashion when the mice were treated
with a proteasome inhibitor (24). Another example of ubiquitin-independent targeting to the
proteasome uses the degron from ornithine decarboxylase (ODC). A 37 amino acid sequence
from the C-terminus of ODC (cODC) is recruited to the proteasome in a ubiquitin-
independent manner, allowing for its use as a proteasome targeting sequence that does not
require the E1-E3 enzymatic cascade (Figure 2c) (25). Stable expression of the ODC-GFP
reporter in mouse models has been used to evaluate proteasome activity. This system has
been shown capable of detecting Bortezomib inhibition of proteasome activity in tumor
cells, indicating that it could be used in the future for library-based screens for proteasome
inhibitors (26). Affinity tags combined with the ODC degron produced a reporter used in
Saccharomyces cerevisiae. This tag allowed for purification and quantification of the
reporter and helped identify strains of yeast with mutations affecting the proteasome (25). A
recent study identified another degron that could be incorporated into a full length protein to
target it for degradation, commonly referred to as a portable degron. The 21 C-terminal
amino acids from the tumor suppressor NKX3.1 (termed the C21 degron) was fused to the
C-terminus of GFP to initiate proteasome-dependent degradation of GFP (27). While it was
not incorporated into a proteasome reporter, the C21 degron exhibits the potential for
monitoring proteasome activity.
Reporters employing other targeting mechanisms have been used to monitor proteasome
activity. Carefully designed small peptide reporters were able to target specific active
subunits of the proteasome. These reporters use fluorophores such as 7-
amino-4methylcoumarin (AMC) or 2-naphtylamine (βNA), which, when cleaved, release a
highly fluorescent product (28). Unlike the previously described techniques, these reporters
are not transfected into the cell; but are added immediately prior to measurement, allowing
direct quantitation of proteasome activity (29). A second generation of these reporters
incorporated the luciferase substrate aminoluciferin instead of a fluorophore, permitting
increased sensitivity (30). FRET-based reporters have also been developed to evaluate
proteasome activity. One such reporter used small peptides that, when degraded by the
proteasome, would exhibit a decreased FRET-behavior and direct measurement of
proteasome activity (31). Finally, a novel reporting technique incorporated a short peptide
along with nuclear magnetic resonance (NMR) to detect cleavage of an isotopically labeled
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reporter (32). This enabled detection of proteasome activity even in optically dense
environments, and has been used to discover potential proteasome inhibitors in the
secretions of Photorhabdus luminescens.
The Two-Component Degron
While the aforementioned proteasome reporters containing degrons fused to various
analytical handles have demonstrated success in evaluating proteasome activity, other
proteasome reporters have been developed using what has been commonly referred to as the
two component degron. These reporters are based on the concept that efficient proteasomal
degradation requires both the degradation sequence and an unstructured region C-terminal to
the degron serves as an initiation region (Figure 2d) (33). While a polyubiquitin chain
consisting of at least four subunits is sufficient for targeting a protein to the proteasome, it
has been demonstrated that this unstructured region acts as an initiation point for the
proteasome to begin substrate degradation (34). The importance of the two-component
degron has been demonstrated in mycobacterium, which used the prokaryotic ubiquitin-like
protein (Pup) in proteasome-mediated degradation (35). However, the importance of
initiation region length and structure was not clearly defined until recently, when researchers
began to utilize novel proteasome reporters consisting of the two-component degron.
The effect of initiation region length was recently clarified using a non-cleavable tetra-
ubiquitin tag (or a UbL) fused to an E. coli DHFR domain along with unstructured C-
terminal tails of different lengths (36). It was determined that the initiation region needs to
be located an appropriate distance relative to the proteasome-binding tag, with the distance
depending upon the proteasome-targeting method. For a polyubiquitin chain, the initiation
region must be adjacent to the ubiquitination site, while an UbL-targeted substrate required
the initiation region to be separated from the UbL domain. The importance of protein
stability was studied using a two-component degron reporter consisting of either cODC or
Rpn10 as the proteasome targeting sequence coupled with either the titin I27 domain or
DHFR, both of which could be switched from a folded to an unstructured state either by a
point mutation or by the addition of a tight-binding ligand respectively (37). These reporters
indicated that increased structural stability corresponded to a decrease in protein degradation
in vivo and with purified proteasome. Another recent study found that the proteasome could
be manipulated to initiate degradation in the middle of a polypeptide chain using a reporter
consisting of an initiation region flanked on either side with folded domains (38). This
reporter showed that while these domains do not directly interact, they do stabilize each
other and effectively decrease proteasome processivity. While these and other studies have
demonstrated the importance of the two-component degron, a recent study suggested that a
polyubiquitin chain was not even necessary for efficient proteasomal targeting (39). This
work revealed that short proteins between ∼20–150 amino acids only required mono-
ubiquitination for proteasome-mediated degradation. These experiments employed multiple
different reporters including non-cleavable, non-polymerizable ubiquitin fused to a poly-His
tag, GFP, and shortened iterations of the DHFR domain. However, if a protein fused to the
ubiquitin was larger than ∼150 amino acids it required polyubiquitination for proteasome-
mediated degradation. These new results provide more information on the role of the two-
component degron and the requirement for mono- vs. poly-ubiquitination to target a protein
for degradation.
The N-end rule pathway
Another strategy to target a protein for degradation exploits the N-end rule, a generalized
rule that governs the protein-destabilizing activity of a given amino-terminal amino acid.
This pathway was initially discovered when the stability of an engineered substrate was
found to be dramatically affected by the identity of its N-terminal residue (40). Following
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this discovery, a hierarchy of amino acids was established with certain residues, like
arginine, being highly destabilizing and other residues, like valine, being fairly stable
(Figure 2e). Similar to the activation of phospho-degrons by kinases, there exists a class of
proteins that are involved in the creation of N-degrons, degrons containing a destabilizing
amino acid at the N-terminus. These N-degrons are then recognized and targeted for
degradation by N-end rule pathway ubiquitin ligases, such as UBR1 in the yeast
Saccharomyces cerevisiae (41). A very comprehensive review detailing the N-end rule in
various model systems including yeast, plants and mammalian cells has recently been
published (42); so for the sake of this review we will only focus on some of the more recent
examples of reporters using the N-end rule. One such reporter was developed based on the
C-terminal proteolytic fragment of BRCA1 generated during apoptosis (43). This reporter
fused ubiquitin to the N-terminus of the BRCA1 fragment such that ubiquitin could be
selectively removed by addition of ubiquitin hydrolase. Removal of the ubiquitin exposed
the N-terminal amino acid to allow the reporter to be targeted by the N-end rule. Different
iterations of the N-terminal amino acid showed that the C-terminal fragment was in fact
being degraded according to the N-end rule. Another recent study developed a short-lived
reporter of transcription by using the N-end rule to control the half-life of the reporter (44).
It consisted of an N-degron version of GFP with only a half-life of ∼ 7 minutes, permitting
precise monitoring of gene expression in living cells. While the N-end rule is a useful
method for targeting proteins for degradation, N-degrons are not normally utilized as
proteasome reporters due to the requirement of an additional protein to create the N-degron,
as well as the consideration that many members of the pathways are still not well
characterized.
Measuring ubiquitination enzyme activity and polyubiquitin chain formation
While many of the preliminary experiments on the UPS have focused solely on protein
degradation, it has become clear that the process of targeting a protein for degradation
involves a substantially greater number of proteins, each with their own specificity and
activity. As a result, new reporting methods were developed to measure both the activity of
the enzymes controlling ubiquitination and deubiquitination as well as to find a way to
quantify the formation of the various linkages of polyubiquitin chains. In this section we
highlight some of the recent advances in reporting technology for E3 ligase activity, DUB
inhibition, and K63-linked polyubiquitin chain formation.
E3 ligase activity
Of the three members composing the enzymatic cascade controlling protein ubiquitination,
the E3 ubiquitin ligases have received the most attention with regards to measuring activity
and developing inhibitors for clinical use. The desire to target this class of enzymes is due to
their abundance (>600 known in humans), specificity, and known role in diseases such as
cancer and neurodegenerative disorders. Many of the initial reporters for E3 ligase activity
were incorporated into a high throughput screening assay in order to evaluate the
effectiveness of inhibitors against the binding of p53 and Mdm2 (or Hdm2 in humans), a
major mechanism of p53 inactivation in tumors. Hyperactivation of Mdm2, the E3 ligase
responsible for the ubiquitination and degradation of p53, causes the accelerated clearance
of p53 and the elimination of its tumor suppression capabilities. An initial assay simply
utilized GST-tagged Hdm2 along with labeled ubiquitin to monitor the auto-ubiquitination
of Hdm2 in the presence of inhibitors during a controlled reaction (45). While this was
effective in studying Hdm2 autoubiquitination, autoubiquitination can occur in the absence
of p53 and, as a result, did not provide information on the specific interaction between p53
and its E3 ligase. Recent work has focused more on the precise interaction between p53 and
Hdm2, especially through the use of high throughput screening to identify compounds which
can inhibit this specific interaction (Figure 3a). An assay utilizing Cy-5 labeled ubiquitin
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(acceptor) and europium-labeled p53 (donor) was employed to measure Mdm2-mediated
ubiquitination by time resolved fluorescent resonance energy transfer (TR-FRET) (46). This
TR-FRET assay was easily adapted to a high-throughput screen which was used to assess
>600,000 compounds for Mdm2-p53 binding inhibition. A similar study screened inhibitors
of the p53-Mdm2 interaction using mammalian two-hybrid technology in tandem with a
dual-luciferase reporter system with the goal of isolating a single compound that induced
growth arrest in tumor cells (47). Large screens of E3 ligase activity have also been
developed for E3 ligases other than Mdm2. One report used protein microarrays to analyze
cell extracts from a mitotic checkpoint system to identify possible substrates of the anaphase
promoting complex (APC), a known E3 ligase essential to the cell cycle (48).
Measuring intracellular E3 ligase activity can be difficult for a variety of reasons, including
the presence of DUBs or the participation of E2 enzymes in substrate ubiquitination. To
overcome the inhibitor effects of DUBs, one group sought to reconstitute the E1-E2-E3
enzymatic cascade in bacteria (49). Co-expression of affinity-tagged substrates and ubiquitin
resulted in purified proteins that were used to study E3 autoubiquitination and map
ubiquitination sites on the E3 ligase Mindbomb. Another study made use of a reporter
consisting of a substrate tethered to an E2 enzyme in order to demonstrate that an E2 could
promote ubiquitination in the absence of the E3 ligase (50). However, this ubiquitination is
highly non-specific and, by using a substrate-fused to an E3 ligase reporter, it was shown
that the E3 ligase actually determines mono- vs. polyubiquitination as well as the type of
polyubiquitin chain linkage. Finally, a number of reporters have been developed that
indirectly monitor E3 ligase activity. A recent study showed that the E3 ligase Smad
ubiquitin regulatory factor-1 (Smurf1) interacts with LIM mineralization protein-1 (LMP-1)
to increase the cellular responsiveness of human bone morphogenetic protein-2 (BMP-2), an
essential protein used clinically to stimulate bone growth (51). Although the reporting
mechanism in this work did not specifically measure E3 ligase activity, it was able to
demonstrate the importance of its activity.
Polyubiquitin chain formation
The manner in which a polyubiquitin chain forms on a substrate can dramatically alter the
fate of the substrate, depending on the number of ubiquitins as well as the manner in which
the chain is linked. As a result, it has become important to develop reporting technologies to
specifically monitor polyubiquitin chain formation. Early work in substrate ubiquitination
utilized bioluminescence resonance energy transfer (BRET) to study G-protein coupled
receptor (GPCR)-mediated β-arrestin 2 ubiquitination (52). The reporter system consisted of
a GFP-ubiquitin fusion protein and a substrate that had been fused to Renilla luciferase
(Rluc). When the GFP-Ub was conjugated to the substrate, the two moieties came into close
proximity with substrate ubiquitination measured by light emission. A similar concept has
been used to study the kinetics of polyubiquitin chain formation using two different
fluorescently labeled ubiquitins, FAM-Ub and TAMRA-Ub, to produce a measurable FRET
signal upon polyubiquitin chain formation (Figure 3b) (53). Another pairwise detection
metric was used in a wheat cell-free protein synthesis system to analyze the ubiquitin
pathway in Arabidopsis and identify E3 ligases (54). This reporting schemed used FLAG-
tagged and biotinylated ubiquitins to produce a luminescent signal by bringing streptavidin-
coated donor beads into proximity of protein A-conjugated acceptor beads during
polyubiquitin chain formation. Additionally, radiolabeled 125I-ubiquitin was used to
elucidate multiple aspects of the E1-E3 enzymatic cascade, such as the stoichiometric
determination of E1 and E2 concentrations and a screen for E2-E3 specificity, solely by
measuring polyubiquitin chain formation (55).
Recent developments in the reporting of polyubiquitin chain formation have provided
insight into the role of K63-linked chains as well as the importance of the conformational
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state on ubiquitin recognition. Using a string of three ubiquitin-interacting motifs (UIMs)
researchers created a reporter that binds to K63-polyUb chains with a 70-fold greater
specificity over K48-linked chains (Figure 3c) (56). This probe was then used as a
competitive inhibitor to study the role of K63-polyUb on NF-κB activation; however this
method has the potential to extend beyond its use as an inhibitor. Similarly, an ubiquitin-
binding domain (UBD)-based fluorescent sensor was developed to monitor linear and K63-
linked chain production with confocal microscopy in response to Salmonella infection, DNA
damage, and mitophagy (57). Further, a novel FRET-based reporter was designed to
examine how different conformational states of ubiquitin chains can impact recognition by
DUBs (58). Using FRET-labeled K63-, K48, and Met1-linked diubiquitin reporters, it was
discovered that the type of lysine linkage conferred either a more ‘open’ or ‘closed’
conformation, which directly correlated with DUB recognition efficiency. While reporting
substrate polyubiquitination is essential, it is also important to monitor the different pools of
ubiquitin found in the cell. A new method called protein standard absolute quantification
(PSAQ) was developed to measure cellular concentrations of ubiquitin species using
isotope-labeled protein standards, selective pull down, and mass spectrometry (59). This
assay was able to map the population of ubiquitin in free, mono-, or polyubiquitin forms
under different experimental conditions such as proteasome inhibition.
Ubiquitin and UbL proteases
Control of the enzymes responsible for the cleavage of the ubiquitin-protein isopeptide bond
has become a central focus in the development of novel inhibitors. As such, new reporting
techniques needed to be developed to characterize the selectivity of these enzymes, as well
as the effectiveness of inhibitors targeting them. The most common type of reporter consists
of a single ubiquitin (or UbL) fused to the N-terminus of the enzyme phospholipase A2
(PLA2). This reporter has shown a great deal of success and works because the PLA2 amino
terminus must be unobstructed for PLA2 catalytic activity. Upon cleavage of the ubiquitin
by a DUB (or UbL by a corresponding protease) the free PLA2 is able to cleave the 2-acyl
linkage of a fluorescent 3-sn-phosphoglyceride, effectively liberating a fluorophore from
this class of molecule (Figure 3d). Ubiquitin and UbL-fused reporters can be used to
discriminate between DUB, deSUMOylase, deNEDDylase, and deISGylase activities, and
ultimately profile nonselective isopeptidase inhibitors (60). Highlighting the success and
popularity of this reporter system, a high-throughput reporter to monitor sentrin specific
proteases (SENPs) for SUMO protease activity is now commercially available (61).
Additionally, an Ub-PLA2 reporter was used in a high-throughput screen to identify
compounds to inhibit the DUB USP7 (62). This screen led to the discovery of a novel
inhibitor that could be used to overcome Bortezomib resistance in multiple myeloma
patients. Further improvements have been made on this reporting scheme enabling the
creation of a multiplexed assay to ascertain inhibitor selectivity (63). By fusing ubiquitin, or
a UbL, to the N-terminus of PLA2 and two other proteins, enterokinase light chain (EKL)
and granzyme B (GZMB), that also require a free amino terminus for activity, researchers
were able to detect three distinct protease activities simultaneously in a single well. This
reporter system was ultimately used to distinguish between selective and non-selective
protease inhibitors. In addition to the previously described reporters, there are other means
of measuring isopeptidase activity that do not utilize the PLA2 strategy. A FRET-based
reporter consisting of YFP-SUMO fused to an enhanced cyan fluorescent protein (ECFP)-
peptide was used to evaluate SUMO protease activity (64). When the protease cleaved
SUMO from the peptide the separation of the two fluorophores resulted in a quenching of
fluorescent signal, allowing effective monitoring of protease activity. This reporting scheme
was demonstrated to have applications in protease characterization, enzyme kinetic analysis,
and high-throughput inhibitor screening.
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Beyond reporting enzymatic activity
In addition to the development of novel reporting techniques, it is important for researchers
to continue to identify new proteins regulated by the ubiquitin proteasome system. Global
high-throughput screening techniques such as stable isotope labeling with amino acids in
cell culture (SILAC) used mass spectrometry in tandem with specific antibodies or siRNA to
identify new E3 ligases or E3 ligase targets (65–67). Conversely, the increase in
computational power and expanding protein databases have allowed researchers to mine for
targets of SUMO ubiquitin ligases, effectively diminishing the need for such costly high-
throughput experiments (68). Additionally, novel degrons have been identified not as
reporters but as controllable degradation signals. The incorporation of degrons into native
proteins has permitted researchers to specifically control degradation through the
incorporation of a ligand-induced degradation (LID) domain (69) or by appending a
hydrophobic moiety to the surface of a protein (70). While these inducible degradation
signals are not currently used for reporting proteasome or E3 ligase activity, they have the
potential to be incorporated into the next round of reporters to provide more diverse
evaluation of the UPS.
Development of a novel UPS substrate based on the β-Catenin degron
A wide array of methods to measure the activity of members of the ubiquitin proteasome are
available and applicable to in vitro assays, single-cell, microscopy-based measurements and
transgenic animal analyses. The methods have been indispensable in identifying new
proteins involved in the UPS, in the discovery of new inhibitors with translational potential,
and in visualizing the role the UPS plays in various diseases. However, these methods are
limited when it comes to the analysis of patient samples. Clinical sample size is often
limited and diseased cells are typically mixed with healthy cells, which severely limit
analytical techniques. For example, in a randomized, multicenter, international phase III
study comparing the clinical use of Bortezomib to dexamethasone (another multiple
myeloma therapeutic) only 156 of 459 samples collected could be used for gene expression
profiling due to low numbers of cells available (71). Additionally, single cells, even those
isolated from the same patient or even tumor site, can exhibit differences in enzyme activity
due to cell heterogeneity necessitating a need for assay systems with the sensitivity for
single-cell measurements (72,73). As such, clinical reporters must be developed that are
easily incorporated into single primary cells and that can be analyzed by quantitative
techniques such as capillary electrophoresis or chemical cytometry. While the previously
described reporters work well with cultured cell lines and transgenic animals, their ability to
translate to clinical samples is impaired due to their need to be genetically engineered into
cells, a technique that is at best extremely difficult with patient samples of limited size.
Further, cultured cell lines have adapted themselves to growing in tissue culture and are very
often not reflective of the biology of cells in vivo (74–76) . To address this need, we sought
to characterize a known degron that could ultimately be incorporated into single cell
reporters to evaluate either E3 ligase or proteasome activity (77). These degron-based
substrates were synthesized using solid phase peptide synthesis, a non-vector based method
which avoids the need for cellular genetic engineering. Previous work in the lab
demonstrated the utility of this technique when evaluating enzymatic activity in single cells
(78,79).
Based on the success of GFPu, the first substrate selected was the CL1 degron; however, the
peptide was difficult to synthesize with sufficient yield and purity using standard Fmoc-
based synthesis. Next, the phospho-degron from β-Catenin (DSGIHSG) was selected based
on its success as a peptide reporter for E3 ligase-mediated ubiquitination. The two serine
residues in this motif are phosphorylated (80). Based on these results, a substrate was
developed based on the β-Catenin degron that included four important components: the
Melvin et al. Page 9













degron (red), a ubiquitination site lysine (yellow), a spacing region to separate the degron
and ubiquitin accepting lysine to avoid potential steric hindrance (blue), and a fluorescein
tag (green) (Figure 4a). The incorporation of the fluorescein tag into the degron-based
substrate simplified detection so that only a fluorescence measurement was needed to
visualize substrate ubiquitination rather than other more complex means such as an
antibody-based detection method. Further, the fluorescence tag also enables future high
sensitivity detection in more precise analytical techniques such as capillary electrophoresis
(10−20 to 10−21 moles of peptide or 10–100 nM peptide in a single cell) (72). During
substrate design it was decided to incorporate three lysines at the C-terminus to improve
peptide solubility by adding an overall positive charge to the sequence and also acted as a
spacer between the bulky fluorophore and the amide resin. The substrates were generated
using standard Fmoc-protected solid phase peptide synthesis (SPPS), purified by reverse-
phase HPLC, and molecular weight confirmed by MALDI-TOF. Finally, a Nanodrop 2000
(Thermo Scientific) was used to measure the fluorescence intensity of all the peptides to
determine both the peptide concentration and ensure that each peptide exhibited the same
level of basal fluorescence.
To confirm that the β-Catenin degron-based substrate could be ubiquitinated, the substrate
was incubated with HeLa S100 cytosolic lysates as the source of E1, E2, and E3 enzymes
(81). Additionally, either exogenous ubiquitin (Ub) or methylated ubiquitin (MeUb) was
incorporated into the assay. Native ubiquitin enabled the formation of polyubiquitin chains
while MeUb eliminated polyubiquitin chain formation due to each lysine residue being
capped with a methyl group allowing for only mono-ubiquitin chain formation. After the in
vitro ubiquitination assay, experimental samples were separated and imaged using gel
electrophoresis and the bands were detected using a Typhoon Imager to visualize the
fluorescein tag. Substrate ubiquitination increased with time when using either Ub or MeUb,
as demonstrated by the hallmark ubiquitin ladder (Figure 4b). Additionally, a pronounced
band at a very low molecular weight was observed in all lanes and could potentially be due
to substrate degradation by cellular peptidases, which remain active in spite of added
protease inhibitors (data not shown). Although these results strongly implicated substrate
ubiquitination, a ubiquitin pull down assay was performed using tandem ubiquitin binding
entity (TUBE) agarose beads (LifeSensors, Malvern, PA) to confirm this (82). To obtain
more quantifiable results, the ubiquitin pull down assay utilized MeUb, instead of
exogenous Ub, to isolate the mono-ubiquitinated substrates at ∼12 kDa (Figure 4b, lane 6–
9). These results verified that the high intensity bands observed from the ubiquitination
assay did, in fact, correspond to ubiquitinated substrate (Figure 4c). Control experiments
were performed to ensure that the results were not the result of non-specific binding between
substrate and agarose bead or basal fluorescent levels of native proteins found in the S100
lysates (data not shown). Based on these controls, it was concluded that all the bands
corresponded to specific substrate ubiquitination, with the higher molecular weight bands
representing di-, tri-, and tetra-ubiquitinated substrates.
While these results do correspond to successful ubiquitination, the presence of higher
molecular weight bands suggested the presence of greater than one ubiquitin per peptide
even in the presence of methylated ubiquitin (Figure 4c). It was calculated that a 100-fold
excess of methylated ubiquitin (45 µM) was added to the assay over endogenous ubiquitin
contained in the S100 lysates (0.3 µM), which suggested that the ubiquitin ladder in the
samples with methylated ubiquitin did not correspond to polyubiquitin chain formation. The
most likely explanation for the higher molecular weight bands was substrate multi-
monoubiquitination, where single ubiquitins are conjugated to different lysine side chains on
the same substrate. Thus the E3 ligase, SCFβTrCP, might not possess absolute fidelity for the
location of the ubiquitination site lysine on this non-native substrate and C-terminal lysine
residues might be readily ubiquitinated in this system. To determine if the above results
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corresponded to multiple single ubiquitins on the same peptide, substrates were redesigned
to replace the three lysines at the C-terminus with three arginines. A subsequent pull-down
assay, using only MeUb to prevent polyubiquitin chain formation, demonstrated that
eliminating these additional lysine residues prevented multimonoubiquitination (Figure 4d,
lane 4) when compared to the initial β-Catenin substrate, which was multi-
monoubiquitinated at the C-terminal lysines (Figure 4d, lane 2). Removal of the C-terminal
lysines resulted in specific mono-ubiquitination of the degron-based substrates (Figure 4d,
arrow). During the redesign, a phospho-mimic was also incorporated through a substitution
of glutamic acid for phosphorylated serine to avoid any potential issues with substrate
dephosphorylation. The pS→E substitution did not reduce substrate ubiquitination (Figure
4c, lane 4 vs. Figure 4d, lane 2), so all further peptide designs possessed this modification.
Based on these results, it was next examined whether the E3 ligase possessed a preference
for the location and proximity of the ubiquitination site lysine by placing the lysine at either
the N- or C-terminal region on either full length or shortened substrates. An earlier study by
Wu and colleagues focusing on SCFβTrCP-mediated β-Catenin ubiquitination found that the
rate of ubiquitination of the degron was strongly dependent on the spacing between the
ubiquitination site lysine and the degron itself (83). To address the issue of proximity
between the ubiquitination site lysine and the degron, substrates were designed either with
or without the ∼6–8 amino acid spacing sequences (Figure 4a, blue region) between the N-
or C-terminal lysines and the degron (Figure 4d). Removal of the additional amino acids on
the peptides with the triple lysine C-terminus demonstrated a pronounced lack of substrate
multi-monoubiquitination, implying that there exists a spatial significance for precise
substrate ubiquitination (Figure 4d lane 2 vs. lane 3). Further, when comparing full length
versus shortened substrates all containing a single ubiquitination site lysine, there was a
noticeable increase in substrate ubiquitination in the full length substrate (Figure 4d lane 5
vs. lane 7) further verifying the need for these ‘spacing’ amino acids between the degron and
the ubiquitination site lysine. Next, the location of the ubiquitination site lysine was studied
to determine the ideal position for maximal substrate ubiquitination. The results obtained
indicated that a C-terminal lysine exhibited greater ubiquitination than an N-terminal lysine
in both full length (Figure 4d lane 4 vs. lane 5) and shortened (Figure 4d lane 7 vs. lane 8)
peptides. Additionally, it was observed that moving the ubiquitination site lysine one residue
in from the C-terminus actually decreased the amount of substrate ubiquitination when
compared to the C-terminal lysine (Figure 4d lane 6 vs. lane 5). Ultimately, this analysis
indicated that there was a slight preference for a C-terminal ubiquitination-site lysine in the
full length peptide (Figure 4d, lane 5); however, all of the peptides were ubiquitinated to
various degrees which suggested that the E3 ligase did not possess an absolute requirement
for a specific location of the lysine.
Finally, it is important to note the presence of the less intense bands found at ∼23 and 29
kDa in the single lysine containing substrates (Figure 4d, asterisk). To address the identity of
these bands, two substrates containing a single C-terminal ubiquitination site lysine (full
length or shortened) were incubated in the ubiquitin pull down assay in the presence of
either MeUb, Ub, or no additional exogenous ubiquitin (Figure 4e). Incubating the two
substrates with Ub resulted in the hallmark polyubiquitin ladder (Figure 4e lane 2, 6), while
the same ladder was also observed in the full length substrate incubated without any
exogenous MeUb or Ub (Figure 4e lane 3). This polyubiquitin ladder, in the absence of
exogenous ubiquitin, is most likely due to the presence of endogenous ubiquitin found in the
HeLa S100 lysates. Additionally, there was a marked increase in polyubiquitination of the
full length substrate when compared with the shortened substrate, verifying what was
previously observed that the ‘spacing’ amino acids are important for efficient substrate
polyubiquitination (Figure 4e lane 2 vs. lane 6). This was observed further in the substrates
incubated without any exogenous ubiquitin, with the shortened substrate lacking any type
polyubiquitination (Figure 4e lane 7). Further, these results indicated that the higher MW
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bands at ∼23 and 29 kDa observed in Figure 4d are not due polyubiquitinated substrate
(Figure 4e lane 1 vs. lane 2). The presence of these bands, after the ubiquitin pull down,
could be attributed to a number of other issues such as non-specific binding of the MeUb-
bound substrate or other modifications. Further work is underway to determine the identity
of these unknown species. Finally, incubating the degron-based substrate with control
agarose beads instead of the agarose-TUBES resulted in no pull down of ubiquitinated
substrate. However, this did confirm that the lower MW bands (< 12 kDa) are most likely
due to non-specific binding of degradation products to the agarose beads (Figure 4e lane 4).
This work highlights the isolation and characterization of a portable degron, based on the β-
TrCP binding site on β-Catenin, which could ultimately be incorporated into a novel
reporter to measure either E3 ligase or proteasome activity in single cells from clinical
samples. It is important to note that the observed results only correspond to substrates based
on the β-Catenin degron and do not translate to β-Catenin ubiquitination by SCFβ -TrCP
under physiological conditions. While the N-terminal lysine found on the original substrate
(Figure 4a) does correspond to the natural lysine position, the additional lysines incorporated
into the C-terminus of the peptides tested are not representative of the native protein.
Finally, one current limitation to this substrate is the rapid degradation in single cells by
non-proteasomal systems (84). As such, current work is underway to further optimize the
portable degron from β-Catenin to confer resistance to intracellular peptidases to create a
more stable reporter. Eventually, these substrates based on portable degrons may exhibit the
potential as new and exciting reporting tools to evaluate UPS activity in patient samples.
Outlook
After the clinical success of the proteasome inhibitor Bortezomib and the approval of the
next generation inhibitor Carfilzomib (9), the development of therapeutics targeting the
ubiquitin proteasome system have become a top priority. Similar to the intensive
development of kinase-focused clinical drugs, inhibitors for the proteasome, E3 ligases,
deubiquitinating enzymes, and UbL proteases are starting to funnel into clinical trials in
greater and greater numbers. However for these inhibitors to succeed, we need to continue to
expand our understanding of this essential pathway. In this review we aspire to briefly
summarize some of the methods used to report the activity and performance of members of
the ubiquitin proteasome system; yet, there is still much to be done in terms of reporter
development. Current reporting techniques have proven successful in demonstrating the
importance of the proteasome in multiple diseases ranging from cancer to neurodegenerative
diseases. Ubiquitin dependent and independent reporters such as GFPu and ODC-GFP have
provided preliminary information on Bortezomib effectiveness. Methods to measure E3
ligase and DUB activity have identified new potential inhibitors to complement proteasome
inhibition by Bortezomib. From high-throughput screening methods to single cell
microscopy these reporters have greatly advanced the understanding and selective targeting
of the UPS. However, while cultured cells have been useful in studying the UPS, methods to
screen patient samples for the enzymatic activity of therapeutic targets such as the
proteasome would greatly benefit clinicians in the diagnosis and treatment of diseases such
as multiple myeloma. As such, the next generation of UPS reporters, especially those used
for drug discovery, need to be compatible with patient samples. This means reporters that
are (1) easily incorporated in patient samples without complex techniques like transfection,
(2) specific for the UPS system and resistant to degradation by other intracellular proteases
and peptidases, and (3) compatible with single cell analysis techniques like capillary
electrophoresis or mass cytometry. In particular, single-cell based technologies have the
potential to reveal the full diversity and intricacies of UPS behavior in cells. Further,
microscopy-based reporters need to be developed that allow for real-time, in vivo imaging
of proteasome activity without the need to sacrifice the test subject. While GFPu- reporters
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have been useful, novel reporters have the potential to further expand on the known role of
the UPS in neurodegenerative disorders such as Huntington’s and Parkinson’s. Through the
development of more versatile reporters, there exists the potential to more accurately assess
UPS activity in a variety of human diseases, providing the foundation for not only more
effective clinical treatment but also greater successful in the discovery of novel therapeutics.
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Figure 1. Overview of the UPS
Posttranslational protein modification by ubiquitin (or ubiquitin-like proteins, UbLs)
requires a cascade of three increasingly diverse enzymes: an E1 ubiquitin activating enzyme,
an E2 ubiquitin conjugating enzyme, and an E3 ubiquitin ligase. Protein ubiquitination starts
with an E1 forming a high energy thioester bond with free ubiquitin, which is recognized
and transferred to the E2 enzyme. Next, an E3 ubiquitin ligase forms a complex with the E2
enzyme to mediate the transfer of ubiquitin in either a direct (RING family) or indirect
(HECT family) manner. Polyubiquitin chains are formed through linkages of one of the
seven lysines present on ubiquitin with K48-linked chains being targeted towards the
proteasome. The 19S cap of the 26S proteasome recognizes the polyubiquitin chain and then
unfolds and degrades the protein into small peptide fragments in the 20S core particle.
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Figure 2. Measuring proteasome activity
Proteasome reporters consist of two major elements; a targeting sequence to recruit the
reporter to the proteasome (usually a degron) and an analytical handle that can produce a
measureable signal (depicted here as the green fluorescent protein (GFP); however other
signals such as luciferase or FLAG tags have been used). Ubiquitin-dependent proteasomal
targeting uses either the 16 amino acid degron from CL1 (A) or a non-cleavable ubiquitin
(B) to measure proteasome activity in response to various conditions such as drug-induced
inhibition. (C) The ubiquitin-independent degron ODC is also recruited to the proteasome
without requiring the E1-E3 enzymatic cascade. (D) A two component degron demonstrates
the importance of an unstructured initiation region for efficient targeting and degradation of
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reporters. (E) The N-end rule governs N-terminal amino acids that are stabilizing (valine) or
destabilizing (arginine).
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Figure 3. Measuring E3 ligase and DUB enzymatic activity and polyubiquitin chain formation
Due to the complex nature of the ubiquitination enzymatic cascade, reporters have been
developed to study a variety of key components. (A) A hallmark E3 ligase reporter was
generated to monitor the interaction between p53 and its E3 ligase Mdm2 primarily using
FRET pairings to evaluate substrate ubiquitination. This method is commonly employed in
high throughput inhibitor screens. Reporters of polyUb chain formation can use multiple
ubiquitin-conjugated fluorophores to detect chain formation by FRET (B) or specific
binding domains to study precise lysine linkages such a K63 or linear polyUb chain
formation (C). (D) The most common method to study Ub (or UbL) proteases such as DUBs
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employs Ub (or UbL) conjugated to the N-terminus of PLA2. Upon cleavage PLA2 is free is
to cleave its substrate effectively liberating a detectable fluorophore.
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Figure 4. Development of a novel UPS substrate based on the β-Catenin degron
(A) Sequence of the degron-based substrate containing four essential components: the β-
Catenin degron (red), an ubiquitination site lysine (yellow), amino acid spacing sequences to
prevent steric hindrance (blue), and a fluorescein tag for detection (green). The bold serines
are phosphorylated. (B) Time-dependent ubiquitination of the degron-based substrate using
either ubiquitin (lanes 2–5) or methylated ubiquitin (lanes 6–9). Lane 1 contains unmodified
substrate (∼3.1 kDa). All bands were detected using a Typhon Imager (GE Healthcare Life
Sciences) to visualize the 5,6 carboxyfluorescein tag. Numbers to the left of the gel
correspond to the apparent molecular weight (in kDa) determined by the known Benchmark
fluorescent protein standard (Invitrogen). (C) Verification of substrate ubiquitination using
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TUBES to selectively pull down ubiquitinated substrate at the indicated times. Assay
samples were incubated with methylated ubiquitin. Suspected mono-, di-, tri-, and tetra-
ubiquitinated substrates are labeled accordingly. (D) Iterative approach to identify the
importance of proximity and location of ubiquitination site lysine on substrate
ubiquitination. All samples were incubated in the in vitro ubiquitination assay for 2 hours
with methylated ubiquitin prior to pull down with TUBES. (E) Two degron-based
substrates, containing a single C-terminal ubiquitination site lysine, were incubated in the in
vitro ubiquitination assay, along with TUBES pull down, under the following conditions:
methylated ubiquitin (lane 1,5), ubiquitin (lane 2,6), no exogenous MeUb or Ub (lane 3,7) or
control-agarose beads instead of the agarose-TUBES (lane 4). Mono-, di-, tri, and tetra-
ubiquitinated species are labeled accordingly.
Melvin et al. Page 24
Cell Biochem Biophys. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
